Long-Term Outcomes with VMAT2 Inhibitors

Author(s):

Jason Noel, PharmD, MPA, BCPP,Julie Dopheide, PharmD, BCPP, FASHP

Panelists discuss how long-term open-label extension studies of VMAT2 inhibitors demonstrated sustained efficacy and tolerability of both deutetrabenazine (ARM-TD and AIM-TD extensions showing durable response over 3 years) and valbenazine (KINECT 4 showing maintained improvements through 48 weeks), with low discontinuation rates due to adverse events and no new safety signals emerging during extended treatment periods.

EP: 1.Optimizing Tardive Dyskinesia Care: Strategies to Advance Treatment Approaches

EP: 2.Diagnosing Tardive Dyskinesia

EP: 3.Impact of Tardive Dyskinesia on Quality of Life

EP: 4.Improving Outcomes Through Patient Education and Addressing Unmet Needs

EP: 5.Treatment Options for Tardive Dyskinesia

Now Viewing

EP: 6.Long-Term Outcomes with VMAT2 Inhibitors

EP: 7.Safety Profile of VMAT2 Inhibitors and Impact on Treatment Selection

EP: 8.Management of Tardive Dyskinesia and Comorbidities

EP: 9.Shared Decision-Making in Tardive Dyskinesia

EP: 10.Strategies for Optimizing Therapy

EP: 11.Patient Journey and the Role of the Pharmacist

EP: 12.Patient Counseling and Management of Adverse Events

EP: 13.Dosing and Titration Considerations

EP: 14.Enhancing Adherence and Collaborative Care

EP: 15.Educational Resources to Support Patients

Video series above is prompted by the following:

What did the following open-label extension studies reveal about the long-term safety and efficacy of the following VMAT2 inhibitors?
Deutetrabenazine
Valbenazine

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!